Walmart Inc. (WMT) shares are recovering on Friday after declining on Thursday following its third-quarter results. The stock was up 2.82% at $129.60 at the time of publication, according to market data.
The quarter itself was solid. Walmart reported adjusted EPS of 65 cents, beating analyst expectations of 64 cents. That figure excludes an after-tax loss of 3 cents per share tied to equity and other investments. Revenue rose 5.2% year over year to $188.835 billion, topping the consensus estimate of $187.271 billion.
But there is a catch, and it lives in the pharmacy aisle. Walmart's weight-loss drug windfall is losing momentum despite rising prescription volumes.
The Pharmacy Drag, Explained
BTIG analyst Robert Drbul reiterated a Buy rating and maintained his $140 price forecast, and his argument is essentially that investors are staring at the wrong number.
Drbul believes Walmart's underlying U.S. business remains healthy, even though Health & Wellness (H&W) is expected to weigh on reported comparable sales. Here is the math: Walmart's 2.9% U.S. comparable sales growth included an approximately 125-basis-point drag from Maximum Fair Price-related pharmacy deflation and brand-to-generic transfers, partly offset by a roughly 60-basis-point contribution from GLP-1 drugs.
Strip out H&W, and comparable sales increased 3.6%, slightly accelerating from the second quarter of fiscal 2027 and improving on a two-year basis. That is the number Drbul is focused on.
Looking ahead, the analyst expects healthy underlying demand but anticipates continued pressure on reported comparable sales from H&W. MFP-related headwinds are expected to remain near current levels or increase slightly, while the contribution from GLP-1 drugs is likely to moderate.
The cushion? Improving H&W gross profit margins should help offset the impact of weaker reported sales, according to the analyst.
Estimates And The Street's Price Targets
Drbul maintained his fiscal 2027 EPS estimate at $2.90 but lowered his fourth-quarter Walmart U.S. comparable sales growth forecast to 2.9% from 3.1%. He still expects comparable sales to increase 3.6% excluding H&W.
He projects fiscal 2027 net sales of $748 billion, representing approximately 6% year-over-year growth, with operating income growing faster than sales. For fiscal 2028, he raised his EPS estimate to $3.25 from $3.15.
Several other analysts raised their price forecasts following the third-quarter results and increased guidance, while maintaining their existing ratings:
- Morgan Stanley analyst Simeon Gutman maintained an Overweight rating and raised his price forecast to $135 from $125.
- Piper Sandler analyst Peter Keith maintained an Overweight rating and increased his price forecast to $138 from $128.
- TD Cowen analyst Max Rakhlenko maintained a Buy rating and raised his price forecast to $147 from $125.
- Truist Securities analyst Scot Ciccarelli maintained a Buy rating and increased his price forecast to $134 from $114.
- BTIG's Drbul reiterated a Buy rating and maintained his $140 price forecast.
The takeaway: the Street is not panicking about pharmacy deflation. It is treating it as a reported-sales problem, not a demand problem. Whether that distinction holds up in the fourth quarter is the thing to watch.